PD-1 Inhibition-Trouble for Subsequent TIL Therapy in Patients with Melanoma?

Area of Science:

• Immunotherapy
• Oncology
• Melanoma Research

Background:

• Investigating the reduced efficacy of adoptive cell transfer (ACT) in melanoma patients pre-treated with anti-PD-1 therapy.
• Assessing tumor mutational burden (TMB), neoantigen load, and tumor-infiltrating lymphocyte (TIL) neoantigen reactivity in this patient cohort.

Discussion:

• Reduced frequencies of neoantigen-specific TILs were observed in patients with lower ACT response.
• This reduction was evident even in patients with comparable TMB, suggesting a mechanism beyond tumor mutational status.
• Findings suggest that prior PD-1 inhibition might negatively impact T-cell expansion and function, crucial for ACT success.

Key Insights:

• Neoantigen-specific TIL frequency is a critical determinant of ACT efficacy in anti-PD-1 experienced melanoma.
• PD-1 blockade may diminish the pool of functional T-cells available for ACT, irrespective of TMB.
• This highlights a potential challenge in optimizing immunotherapy sequencing for melanoma treatment.

Outlook:

• Further research is needed to elucidate the precise mechanisms by which PD-1 inhibition affects T-cell outgrowth for ACT.
• Strategies to overcome PD-1-mediated T-cell suppression could enhance ACT efficacy in previously treated melanoma patients.
• Exploring alternative or combination immunotherapies may be warranted for this patient population.